The Drug Enforcement Administration this week proposed reducing aggregate production quotas for five opioid controlled substances in 2020. The proposal would reduce the amounts of fentanyl by 31%, hydrocodone by 19%, hydromorphone by 25%, oxycodone by 9% and oxymorphone by 55%. The five opioid substances were subject to special scrutiny following the enactment last year of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, which requires DEA to estimate the amount of diversion of the covered substance that occurs in the United States and make appropriate quota reductions. DEA will accept comments on the 2020 proposed aggregate production quotas, which address more than 250 Schedule I and II controlled substances, through Oct. 15.

Related News Articles

Headline
The opioid crisis cost the U.S. economy $631 billion from 2015-2018, according to a report released by the Society of Actuaries.
Headline
The AHA and six other organizations today submitted comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas.
Headline
The Food and Drug Administration Oct. 11 approved a new tablet for the acute treatment of migraine headache pain.
Headline
The AHA today urged the Drug Enforcement Administration to explicitly consider drug shortages when setting and adjusting aggregate production quotas, citing…
Headline
The Department of Health and Human Services today released a guide to help clinicians who are contemplating or initiating a reduction in opioid dosage or…
Blog
AHA featured in numerous media publications.